Merck & Co., Inc. vs PPG Industries, Inc. — how do they compare? Merck & Co., Inc. trades at $146.31 (market cap $351.28B), while PPG Industries, Inc. trades at $104.92 (market cap $23.44B). The key difference: Merck & Co., Inc. is far larger — about 15× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and PPG Industries, Inc. for 68 Days on average.
| MRK | PPG | |
|---|---|---|
Market Cap | $351.28B | $23.44B |
Volume | 7,969,665 | 2,064,777 |
Sector | Health | Basic Materials |
52-Week High | $156.43 | $131.56 |
52-Week Low | $82.49 | $94.34 |
Typical Hold Time | 98 Days | 68 Days |
Enterprise Value | $398.04B | $29.31B |
Dividend Yield | 2.39% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
PPG Industries trades at $104.79, down 0.28% for the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported 2025 revenue of $15.88 billion and net income of $1.58 billion, with a P/E ratio of 15.13. Recent earnings showed mixed results, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Analyst consensus is a Buy with a $130 price target, while recent news highlights margin pressures in the Automotive Refinish segment.
The outlook for PPG is cautiously optimistic, supported by strong profitability metrics like a 9.57% net income margin and 19.63% ROE, but risks include segment-specific weaknesses and macroeconomic headwinds. Upside potential exists if the company meets Q3 2026 earnings expectations and sustains cost-control measures, though investors should monitor auto refinish performance and global demand trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →